Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on November 13, 2013. The report discloses significant changes in executive leadership and associated compensatory arrangements effective as of the filing date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and executive compensation details.
Material Changes
- Promotion: Giovanni Caforio, M.D., was promoted from President, U.S., to Executive Vice President and Chief Commercial Officer, effective November 13, 2013.
- Role Transition: Beatrice Cazala, Executive Vice President, Commercial Operations (Global Commercialization, Europe and China), ceased serving as an executive officer and is transitioning to a new role within the company.
Management Commentary and Compensation Details
In connection with Dr. Caforio's promotion, the following compensation package was established:
- Base Salary: $875,000 annually.
- Annual Bonus: Target opportunity of 100% of base salary under the Senior Executive Performance Incentive Plan, contingent on pre-established performance goals.
- Long-Term Incentives: Participation in the standard annual program, including eligibility for performance share units and market share units under the 2012 Stock Award and Incentive Plan.
- Severance: Change-in-control and severance benefits consistent with those provided to Named Executive Officers in the event of involuntary termination without cause.
The filing states there are no related party transactions or special understandings regarding Dr. Caforio's selection.
Investor Verification Checklist
- Verify the specific terms of the "new role" for Beatrice Cazala to assess potential impacts on Global Commercialization operations in Europe and China.
- Review the attached press release (Exhibit 99.1) for broader strategic context regarding the leadership restructuring.
- Confirm the performance metrics tied to Dr. Caforio's 100% target bonus opportunity in future filings or proxy statements.